PRESS RELEASE : Aladdin Healthcare Technologies jointly develops AI-Platform for Cardiovascular Diseases that achieves three Patents in China

DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Patent/Miscellaneous 
Aladdin Healthcare Technologies jointly develops AI-Platform for Cardiovascular Diseases that achieves three Patents in 
China 
2021-02-24 / 07:59 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Aladdin Healthcare Technologies jointly develops AI-Platform for Cardiovascular Diseases that achieves three Patents in 
China 
- Aladdin has developed patented AI-platform together with its partner IIAT in China 
- The innovative AI-driven platform marks a turning point in the early diagnostics of heart diseases 
- Next step is gaining patent approval also in the USA and Europe 
BERLIN/LONDON February 24, 2021 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading 
developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, has developed 
together with its partner IIAT (Imperial Institute of Advanced Technology) an innovative AI-powered data analysis 
platform for cardiovascular diseases. The platform has just successfully gained three patents in China. 
Aladdin achieves a milestone in the early diagnostics of cardiovascular diseases. By combining multimodal data 
specifically integrated AI-driven blood analysis, the Company brings a novel approach of early diagnostics to market. 
Moreover, most other currently available AI approaches reflect the reliance of the industry on utilising cardiac images 
as a singular approach methodology. This is only adequate for basic diagnosis and does not approach the multiple 
complexities that involve the disease and its underlying pathways. 
The AI-data platform has gained three patents in China that include: 
a. Automated Multimodal Cardiac Image Analysis, Visualisation and 3D Printing 
b. Multiscale Auto-focused Super-resolution 
c. High-resolution Myocardial Motion Analysis System 
The IIAT has been established by a team of royal academicians and professors from Imperial College London and Royal 
Brompton Hospital. It is a new research and development institute engaging the international exchange and cooperation 
in science and technology, Chinese-European technology transfer, and research in medical imaging technology. It is also 
committed to bringing human resources, technologies as well as projects in the field of healthcare from Europe to China 
and promoting them in China. 
Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies, comments: "The achievement of three patents in China is a 
further acknowledgment of our ability in improving the world of healthcare diagnostics with our expertise and together 
with our important network of international partners." Under the agreement with IIAT, Aladdin has all international 
rights to license the AI-technology in Europe, UK and the USA, but not in China. The Company is planning to seek patent 
approval in the USA and Europe as next step. 
As part of the new international growth strategy, Aladdin will list its shares on the OTC market in the USA. 
About Aladdin Healthcare Technologies SE 
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading 
developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease 
diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus 
on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare 
ecosystem to confidentially and securely gather targeted data including genome, tabular, MRI, PET, cognition and other 
lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools 
that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new 
diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug 
discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict 
outcomes more accurately. 
Website Link: www.aladdinid.com 
GSIN: A12ULL 
ISIN: DE000A12ULL2 
TICKER SYMBOL: NMI 
For further information: 
Aladdin Healthcare Technologies Ltd. 
24-26 Baltic Street West 
London EC1Y 0UR 
Phone [phone] 
Email: [e-mail] 
Contact Press 
CROSS ALLIANCE communication GmbH 
Sara Pinto 
Phone [phone] 
Email: [e-mail] 
www.crossalliance.de 
=---------------------------------------------------------------------------------------------------------------------- 
2021-02-24 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Aladdin Healthcare Technologies SE 
              Unter den Linden 10 
              10117 Berlin 
              Germany 
Phone:        [phone] 
E-mail:       [e-mail] 
Internet:     www.aladdinid.com 
ISIN:         DE000A12ULL2 
WKN:          A12ULL 
Listed:       Regulated Market in Dusseldorf 
EQS News ID:  1170650 
 
End of News   DGAP News Service 
=------------ 

1170650 2021-02-24

(END) Dow Jones Newswires

February 24, 2021 02:00 ET (07:00 GMT)